

| | • • • • • |
|---|---|
| | $\bullet \bullet \bullet \bullet \bullet \bullet$ |
| | |
| ARIES [®] SARS-CoV-2 (CE-IVD) Assay | $\bullet \bullet \bullet \bullet \bullet \bullet$ |
| | • • • • • • |
| | • • • • • • |
| | • • • • • |
| | • • • • • |

The ARIES[®] SARS-CoV-2 Assay is a real-time RT-PCR-based in vitro diagnostic test that qualitatively detects SARS-CoV-2 nucleic acid from nasopharyngeal swab (NPS) samples in UTM[™], Liquid Amies (ESwab[™]), or equivalent.

The ARIES[®] SARS-CoV-2 CE-IVD Assay offers:

- Fully Integrated Testing: Automate all aspects of testing, from sample preparation through analysis, in a self-contained cassette.
- Flexible Throughput: In two hours, process from 1 to 12 tests per batch; both STAT testing and medium volume sample batching are supported.
- A Versatile Portfolio: With a growing portfolio of cassette-ready assays and the tools to create laboratory developed tests (LDTs)*, ARIES* Systems deliver reliable detection for a wide range of testing needs.
- **Reliable Performance:** In addition to sensitive detection of SARS-CoV-2 through the ORF1ab and N gene targets, a sample processing control included in the cassette confirms result validity.

Performance

A limit of detection (LoD) study was performed to evaluate the analytical sensitivity of the ARIES[®] SARS-CoV-2 Assay using one strain of the SARS-CoV-2, isolate USA-WA1/2020.

The confirmed ARIES SARS-CoV-2 Assay LoD concentration is 3.00 x 10³ GCE/mL.

Combined Clinical Performance of the ARIES® SARS-CoV-2 Assay for the SARS-CoV-2 Target

| Reference Method Result | Number of Samples Tested | Positive | Negative | % Agreement with Reference Method | |
|----------------------------|--------------------------|----------|----------|-----------------------------------|--------|
| Positive | 89* | 85 | 4† | РРА | 95.5% |
| Negative | 85 | 0 | 85 | NPA | 100.0% |
| Total | 174 | | | | |

*Includes 30 contrived ESwab™ specimens.

[†]Three of the four false negative (FN) specimens were confirmed negative and one was positive for SARS-CoV-2 by PCR followed by bidirectional sequencing.

Workflow



Due to its optimized PCR protocol, the ARIES® SARS-CoV-2 Assay cannot be run in the same magazine as other ARIES® CE-IVD assays.

Ordering Information

| Product Name | Part Number | |
|--|-----------------|--|
| ARIES [®] SARS-CoV-2 Assay (24 Tests) | 50-10051 | |
| ARIES* Two Module System | ARIES-M12V1-IVD | |
| ARIES [®] M1 System | ARIES-M6V1-IVD | |
| SYNCT [™] Software | CN-SW47 | |

Products are CE Marked for IVD use.



orders@luminexcorp.com or support@luminexcorp.com

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at support@luminexcorp.com to obtain the appropriate product information for your country of residence. Validation of the LIS compatibility must be performed by the end user. ARIES[®] Systems are class 1(1) laser products.

*Luminex does not endorse the use of any LDT for diagnostic use.

©2021 Luminex Corporation. All rights reserved. Luminex and ARIES are trademarks of Luminex Corporation, registered in the US and other countries. SYNCT is a trademark of Luminex Corporation. ESwab is a registered trademark of Copan Italia S.P.A.

luminexcorp.com

| : | HEADQUARTERS | | | | |
|---|----------------------|------------------------|----------------------|------------------------|------------------------|
| : | UNITED STATES | EUROPE | CANADA | CHINA | JAPAN |
| ÷ | +1 512 219 8020 | +31 73 800 1900 | +1 416 593 4323 | +86 21 8036 9888 | +81 3 5545 7440 |
| ÷ | info@luminexcorp.com | europe@luminexcorp.com | info@luminexcorp.com | infocn@luminexcorp.com | infojp@luminexcorp.com |

SS308164